Oragenics
OGEN
About: Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Employees: 5
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
602% more capital invested
Capital invested by funds: $57.2K [Q1] → $402K (+$344K) [Q2]
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
6% more funds holding
Funds holding: 17 [Q1] → 18 (+1) [Q2]
0.45% more ownership
Funds ownership: 0.04% [Q1] → 0.49% (+0.45%) [Q2]
Financial journalist opinion